GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Innoviva Inc (NAS:INVA) » Definitions » Altman Z-Score

Innoviva (Innoviva) Altman Z-Score

: 2.06 (As of Today)
View and export this data going back to 2004. Start your Free Trial

The Altman Z-Score is a model designed to predict the likelihood of a company going bankrupt within the next two years. Created by American finance professor Edward Altman in 1968, the model is specifically designed for publicly traded manufacturing companies with assets greater than $1 million.

Warning Sign:

Altman Z-score of 2.05 is in the grey area. This implies that the company is under some kind of financial stress. If it is below 1.8, the company may face bankruptcy risk.

Innoviva has a Altman Z-Score of 2.06, indicating it is in Grey Zones. This implies that Innoviva is in some kind of financial stress. If it is below 1.81, the company may face bankrupcy risk.

The zones of discrimination were as such:

When Altman Z-Score <= 1.8, it is in Distress Zones.
When Altman Z-Score >= 3, it is in Safe Zones.
When Altman Z-Score is between 1.8 and 3, it is in Grey Zones.

The historical rank and industry rank for Innoviva's Altman Z-Score or its related term are showing as below:

INVA' s Altman Z-Score Range Over the Past 10 Years
Min: -3.84   Med: 2.06   Max: 3.58
Current: 2.05

During the past 13 years, Innoviva's highest Altman Z-Score was 3.58. The lowest was -3.84. And the median was 2.06.


Innoviva Altman Z-Score Historical Data

The historical data trend for Innoviva's Altman Z-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Innoviva Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Altman Z-Score
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.63 2.88 3.58 1.97 2.15

Innoviva Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Altman Z-Score Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.97 2.00 2.08 1.55 2.15

Competitive Comparison

For the Biotechnology subindustry, Innoviva's Altman Z-Score, along with its competitors' market caps and Altman Z-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Innoviva Altman Z-Score Distribution

For the Biotechnology industry and Healthcare sector, Innoviva's Altman Z-Score distribution charts can be found below:

* The bar in red indicates where Innoviva's Altman Z-Score falls into.



Innoviva Altman Z-Score Calculation

Altman Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.

Innoviva's Altman Z-Score for today is calculated with this formula:

Z=1.2*X1+1.4*X2+3.3*X3+0.6*X4+1.0*X5
=1.2*0.2461+1.4*-0.0203+3.3*0.1715+0.6*1.6348+1.0*0.2497
=2.06

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency. GuruFocus does not calculate Altman Z-Score when X4 or X5 value is 0.

Trailing Twelve Months (TTM) ended in Dec. 2023:
Total Assets was $1,243.5 Mil.
Total Current Assets was $344.2 Mil.
Total Current Liabilities was $38.1 Mil.
Retained Earnings was $-25.2 Mil.
Pre-Tax Income was 61.201 + 85.952 + 5.805 + 41.14 = $194.1 Mil.
Interest Expense was -5.952 + -4.396 + -4.382 + -4.427 = $-19.2 Mil.
Revenue was 85.84 + 67.259 + 80.992 + 76.372 = $310.5 Mil.
Market Cap (Today) was $929.4 Mil.
Total Liabilities was $568.6 Mil.

* Note that for stock reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data.

X1=Working Capital/Total Assets
=(Total Current Assets - Total Current Liabilities)/Total Assets
=(344.219 - 38.134)/1243.507
=0.2461

X2=Retained Earnings/Total Assets
=-25.189/1243.507
=-0.0203

X3=Earnings Before Interest and Taxes/Total Assets
=(Pre-Tax Income - Interest Expense)/Total Assets
=(194.098 - -19.157)/1243.507
=0.1715

X4=Market Value Equity/Book Value of Total Liabilities
=Market Cap/Total Liabilities
=929.442/568.552
=1.6348

X5=Revenue/Total Assets
=310.463/1243.507
=0.2497

The zones of discrimination were as such:

Distress Zones - 1.81 < Grey Zones < 2.99 - Safe Zones

Innoviva has a Altman Z-Score of 2.06 indicating it is in Grey Zones.

Study by Altman found that companies that are in Distress Zone have more than 80% of chances of bankruptcy in two years.


Innoviva  (NAS:INVA) Altman Z-Score Explanation

X1: The Working Capital/Total Assets (WC/TA) ratio is a measure of the net liquid assets of the firm relative to the total capitalization. Working capital is defined as the difference between current assets and current liabilities. Ordinarily, a firm experiencing consistent operating losses will have shrinking current assets in relation to total assets. Altman found this one proved to be the most valuable liquidity ratio comparing with the current ratio and the quick ratio. This is however the least significant of the five factors.

X2: Retained Earnings/Total Assets: the RE/TA ratio measures the leverage of a firm. Retained earnings is the account which reports the total amount of reinvested earnings and/or losses of a firm over its entire life. Those firms with high RE, relative to TA, have financed their assets through retention of profits and have not utilized as much debt.

X3, Earnings Before Interest and Taxes/Total Assets (EBIT/TA): This ratio is a measure of the true productivity of the firm's assets, independent of any tax or leverage factors. Since a firm's ultimate existence is based on the earning power of its assets, this ratio appears to be particularly appropriate for studies dealing with corporate failure. This ratio continually outperforms other profitability measures, including cash flow.

X4, Market Value of Equity/Book Value of Total Liabilities (MVE/TL): The measure shows how much the firm's assets can decline in value (measured by market value of equity plus debt) before the liabilities exceed the assets and the firm becomes insolvent.

X5, Revenue/Total Assets (S/TA): The capital-turnover ratio is a standard financial ratio illustrating the sales generating ability of the firm's assets.

Read more about Altman Z-Score and the original research.


Be Aware

Altman Z-Score does not apply to financial companies.


Innoviva Altman Z-Score Related Terms

Thank you for viewing the detailed overview of Innoviva's Altman Z-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Innoviva (Innoviva) Business Description

Traded in Other Exchanges
Address
1350 Old Bayshore Highway, Suite 400, Burlingame, CA, USA, 94010
Innoviva Inc develops biopharmaceutical drugs in the antibiotic, respiratory, and digestive realms. Theravance's respiratory compounds are in late-stage trials for asthma and chronic obstructive pulmonary disease. Its product offering includes Relvar/Breo/Ellipta, Anoro, Ellipta, Trelegy, Ellipta and others. The firm collaborates with and receives funding from GlaxoSmithKline.
Executives
Marianne Zhen officer: Chief Accounting Officer C/O INNOVIVA, INC., 2000 SIERRA POINT PARKWAY, SUITE 500, BRISBANE CA 94005
Stephen Basso officer: Chief Financial Officer C/O INOZYME PHARMA, INC., 321 SUMMER STREET, SUITE 400, BOSTON MA 02210
Margaret Koziel officer: Chief Medical Officer C/O AXCELLA HEALTH INC., 840 MEMORIAL DRIVE, CAMBRIDGE MA 02139
Alexander J Denner 10 percent owner C/O SARISSA CAPITAL MANAGEMENT LP, 660 STEAMBOAT ROAD, 3RD FLOOR, GREENWICH CT 06830
Deborah Birx director 3300 LOWELL STREET NW, WASHINGTON DC 20008
Sarissa Capital Management Lp 10 percent owner 660 STEAMBOAT ROAD, GREENWICH CT 06830
Pavel Raifeld officer: Chief Executive Officer 1350 OLD BAYSHORE HIGHWAY, SUITE 400, BURLINGAME CA 94010
Sapna Srivastava director C/O MYOS CORPORATION, 45 HORSEHILL ROAD, SUITE 106, CEDAR KNOLLS NJ 07927
Larry G. Edwards officer: CEO of La Jolla Pharmaceutical C/O TETRAPHASE PHARMACEUTICALS, INC., 480 ARSENAL STREET, SUITE 110, WATERTOWN MA 02472
Plc Glaxosmithkline 10 percent owner 980 GREAT WEST ROAD, BRENTFORD MIDDLESEX X0 TW8 9GS
Mark Dipaolo director 660 STEAMBOAT ROAD, 3RD FLOOR, GREENWICH CT 06830
Kostas D Odysseas director 660 STEAMBOAT ROAD, 3RD FLOOR, GREENWICH CT 06830
Sarah J. Schlesinger director C/O ARIAD PHARMACEUTICALS, 26 LANDSDOWNE STREET, CAMBRIDGE MA 02139
Jules Haimovitz director 601 108TH AVENUE NE, SUITE 1200, BELLEVUE WA 98004
George Bickerstaff director C/O VION PHARMACEUTICALS, INC., 4 SCIENCE PARK, NEW HAVEN CT 06511